文献速递妇科肿瘤消化系统肿瘤泌尿男性生殖肿瘤

德曲妥珠单抗在HER2表达实体瘤患者中的疗效与安全性:DESTINY-PanTumor02 II期试验主要结果

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
PubMed 文献 · J Clin Oncol · 2023-10-23

这项开放标签II期研究评估德曲妥珠单抗(T-DXd,5.4 mg/kg 每3周一次)用于HER2表达(IHC 3+/2+)的局部晚期或转移性实体瘤患者,共267例纳入七个瘤种队列。总客观缓解率(ORR)为37.1%,中央检测HER2 IHC 3+患者ORR为61.3%;≥3级药物相关不良事件发生率为40.8%,10.5%发生药物相关间质性肺病(ILD),其中3例死亡。

要点

  • T-DXd在HER2表达实体瘤中总ORR为37.1%,所有瘤种队列均观察到缓解。
  • 中央检测HER2 IHC 3+患者ORR达61.3%,中位PFS 11.9个月,中位OS 21.1个月。
  • ≥3级药物相关不良事件发生率40.8%,10.5%发生药物相关ILD,其中3例死亡。

核心结论

  • 研究显示,经治的HER2表达实体瘤患者接受T-DXd可获得持久临床获益和有意义的生存结局,安全性与其已知特征(包括ILD)一致。
  • HER2 IHC 3+人群观察到最大获益。
  • 这些数据支持T-DXd作为HER2表达实体瘤潜在肿瘤不可知疗法的作用。

研究设计与样本

  • 开放标签II期研究,评估T-DXd(5.4 mg/kg 每3周一次)用于HER2表达(IHC 3+/2+,经当地或中央检测)的局部晚期或转移性疾病患者,要求既往接受≥1线全身治疗或无替代治疗。
  • 主要终点为研究者评估的确认客观缓解率(ORR),次要终点包括安全性、缓解持续时间(DOR)、无进展生存期(PFS)和总生存期(OS)。
  • 主要分析时共267例患者接受治疗,分布于七个肿瘤队列:子宫内膜癌、宫颈癌、卵巢癌、膀胱癌、胆道癌、胰腺癌和其他。
  • 中位随访时间为12.75个月。

主要发现

  • 全部患者ORR为37.1%(n=99;95% CI 31.3至43.2),所有队列均观察到缓解;中位DOR为11.3个月(95% CI 9.6至17.8);中位PFS为6.9个月(95% CI 5.6至8.0);中位OS为13.4个月(95% CI 11.9至15.5)。
  • 中央检测HER2 IHC 3+患者(n=75)ORR为61.3%(95% CI 49.4至72.4),中位DOR为22.1个月(95% CI 9.6至未达到),中位PFS为11.9个月(95% CI 8.2至13.0),中位OS为21.1个月(95% CI 15.3至29.6)。
  • ≥3级药物相关不良事件发生率为40.8%;10.5%发生经判定的药物相关间质性肺病(ILD),其中3例死亡。

关键数值与推荐

  • T-DXd给药方案为5.4 mg/kg 每3周一次。
  • HER2表达定义为免疫组化(IHC)3+/2+,经当地或中央检测。
  • 入组要求为既往接受≥1线全身治疗或无替代治疗的局部晚期或转移性疾病患者。

临床怎么用

  • 原文结论指出这些数据支持T-DXd作为HER2表达实体瘤潜在肿瘤不可知疗法的作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. Treatments are limited for other HER2-expressing solid tumors. METHODS: This open-label phase II study evaluated T-DXd (5.4 mg/kg once every 3 weeks) for HER2-expressing (immunohistochemistry [IHC] 3+/2+ by local or central testing) locally advanced or metastatic disease after ≥1 systemic treatment or without alternative treatments. The primary end point was investigator-assessed confirmed objective response rate (ORR). Secondary end points included safety, duration of response, progression-free survival (PFS), and overall survival (OS). RESULTS: At primary analysis, 267 patients received treatment across seven tumor cohorts: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other. The median follow-up was 12.75 months. In all patients, the ORR was 37.1% (n = 99; [95% CI, 31.3 to 43.2]), with responses in all cohorts; the median DOR was 11.3 months (95% CI, 9.6 to 17.8); the median PFS was 6.9 months (95% CI, 5.6 to 8.0); and the median OS was 13.4 months (95% CI, 11.9 to 15.5). In patients with central HER2 IHC 3+ expression (n = 75), the ORR was 61.3% (95% CI, 49.4 to 72.4), the median DOR was 22.1 months (95% CI, 9.6 to not reached), the median PFS was 11.9 months (95% CI, 8.2 to 13.0), and the median OS was 21.1 months (95% CI, 15.3 to 29.6). Grade ≥3 drug-related adverse events were observed in 40.8% of patients; 10.5% experienced adjudicated drug-related interstitial lung disease (ILD), with three deaths. CONCLUSION: Our study demonstrates durable clinical benefit, meaningful survival outcomes, and safety consistent with the known profile (including ILD) in pretreated patients with HER2-expressing tumors receiving T-DXd. Greatest benefit was observed for the IHC 3+ population. These data support the potential role of T-DXd as a tumor-agnostic therapy for patients with HER2-expressing solid tumors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2023. PMID: 37870536. doi:10.1200/JCO.23.02005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。